Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (101-110 of 231) with videos related to

Pageof 24
Sort By:
Blood|June 20, 2007
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cellsErnesto Pérez-Persona, María-Belén Vidriales, Gema Mateo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA studyMeletios A Dimopoulos, Paul G Richardson, Rudolf Schlag, et al.
Blood|July 15, 2010
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneJean-Luc Harousseau, Antonio Palumbo, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
British Journal of Haematology|May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myelomaShaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
British Journal of Haematology|March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trialPaul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.
Frontiers in Oncology|November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaLaura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
Pageof 24

Showing results (101-110 of 231) with videos related to

Sort By:
Pageof 24
Blood|June 20, 2007
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cellsErnesto Pérez-Persona, María-Belén Vidriales, Gema Mateo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA studyMeletios A Dimopoulos, Paul G Richardson, Rudolf Schlag, et al.
Blood|July 15, 2010
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneJean-Luc Harousseau, Antonio Palumbo, Paul G Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
British Journal of Haematology|May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myelomaShaji Kumar, Philippe Moreau, Parameswaran Hari, et al.
The Lancet. Haematology|October 4, 2023
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
British Journal of Haematology|March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trialPaul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.
Frontiers in Oncology|November 29, 2023
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myelomaLaura Rosiñol, Benjamin Hebraud, Albert Oriol, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
Pageof 24